The global diabetes market is experiencing a surge driven by the increasing prevalence of this chronic disease. At the forefront of this evolution are leading manufacturers of GLP-1 receptor agonists, a class of drugs that have revolutionized diabetes treatment. These innovative medications dupli

Bachem has shocked the pharmaceutical industry with its massive $2.3 billion acquisition of AmWiner, marking one of the largest deals in the peptide therapeutics sector this year. This strategic takeover signals Bachem's ambitious plans to dominate the growing market for peptide-based medications